Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia

Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) is a controversial diagnosis, as others propose that it represents chronic myelogenous leukemia in blast phase (CML-BP). NPM1 mutations occur in 25–35% of patients with AML but are absent in patients with CML. Conversely, ABL1 mutations occur in 25% of imatinib-naive patients with CML-BP but are not described in patients with AML. We analyzed for NPM1 and ABL1 mutations in nine Ph+ patients with AML and five patients with CML-BP initially presenting in BP. In six cases of Ph+ AML, we screened for a panel of gene mutations using Sequenome®-based methods including AKT1, AKT2, AKT3, BRAF, EGFR, GNAQ, GNAS, IDH1, IDH2, KRAS, MET, NRAS, PIK3CA and RET. Two of nine (22%) patients with Ph+ AML had NPM1 mutations and were alive 36 and 71 months after diagnosis. All cases of Ph+ AML were negative for ABL1 and other gene mutations. One (20%) patient with CML-BP had ABL1 mutation; no patients had NPM1 mutations. These data suggest that Ph+ AML is distinct from CML-BP.

[1]  R. Lipton,et al.  Mutation analysis , 2019, Definitions.

[2]  K. Patel,et al.  Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis. , 2011, The Journal of molecular diagnostics : JMD.

[3]  C. Preudhomme,et al.  Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia , 2011, Leukemia.

[4]  Simona Soverini,et al.  BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. , 2011, Blood.

[5]  M. Barton.  Discontinuation of imatinib may be possible in chronic myelogenous leukemia , 2011, CA: a cancer journal for clinicians.

[6]  A. Kohlmann,et al.  A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases , 2011, Leukemia.

[7]  T. Haferlach,et al.  Subclones with the t(9;22)/BCR‐ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations , 2011, British journal of haematology.

[8]  J. Cortes,et al.  Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays , 2010, Cancer science.

[9]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Caligiuri,et al.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[12]  S. Pileri,et al.  Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia , 2009, Leukemia.

[13]  Liuda Ziaugra,et al.  SNP Genotyping Using the Sequenom MassARRAY iPLEX Platform , 2009, Current protocols in human genetics.

[14]  P. D. Dal Cin,et al.  Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. , 2007, American journal of clinical pathology.

[15]  W. Hiddemann,et al.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.

[16]  J. Cayuela,et al.  Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. , 2005, Blood.

[17]  S. McWeeney,et al.  High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. , 2005, Blood.

[18]  L. Jeffrey Medeiros,et al.  Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type , 2005, British journal of haematology.

[19]  Susan O'Brien,et al.  Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate , 2005, Clinical Cancer Research.

[20]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[21]  L. Medeiros,et al.  Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. , 2004, American journal of clinical pathology.

[22]  M. Pettenati,et al.  Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. , 2004, Leukemia research.

[23]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[24]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[25]  L. Medeiros,et al.  Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. , 2001, American journal of clinical pathology.

[26]  D. Neuberg,et al.  Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience , 1998, Leukemia.

[27]  H. Heimpel,et al.  Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients , 1996, Annals of Hematology.

[28]  H. Kantarjian,et al.  Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. , 1987, The American journal of medicine.

[29]  C. Bloomfield,et al.  The philadelphia chromosome in acute leukemia , 1978, Virchows Archiv. B, Cell pathology.

[30]  C. Yoshida.  [Chronic myelogenous leukemia]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[31]  Hideki Makishima,et al.  [Deep sequencing]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[32]  M. Baccarani,et al.  IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis , 2011, Leukemia.

[33]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[34]  P. Cin,et al.  Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. , 1996, Haematologica.

[35]  R. Berger.  Differences between blastic chronic myeloid leukemia and Ph-positive acute leukemia. , 1993, Leukemia & lymphoma.

[36]  N. Tupitsyn,et al.  [Ph'-positive acute leukemia]. , 1989, Gematologiia i transfuziologiia.